[Practical management of PARP inhibitors: A French DELPHI consensus].

Date publication

septembre 2022

Journal

Bulletin du cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr KURTZ Jean-Emmanuel , Pr SCHMITT Antonin

Tous les auteurs :
Selle F, Boffa JJ, Etienne G, Angelergues A, Augereau P, Berton D, Dielenseger P, Fabbro M, Falandry C, Follana P, Gladieff L, Joly F, Kurtz JE, Matta C, Mouret-Reynier MA, Schmitt A, Scotté F, Marjollet C, Floquet A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36109248

Résumé

Despite an increasing number of therapeutic indications, there are no specific recommendations regarding the management of PARP inhibitors other than what is specified in the SmPC of each substance. A Delphi French consensus was conducted to establish practical guidelines to meet the needs identified by healthcare professionals and patients.

Mots clés

Breast cancer, Cancer de la prostate, Cancer de l’ovaire, Cancer du pancréas, Cancer du sein, Consensus Delphi, Delphi consensus, Inhibiteurs de PARP, Ovarian cancer, PARP inhibitors, Pancreatic cancer, Prostate cancer

Référence

Bull Cancer. 2022 09 12;: